Mohammad AskarPublic working copy · medical review pending

Glaucoma · 011

Open-angle glaucoma: confirm the mechanism and protect vision

Assess pressure, optic nerve, visual field and angle together. Distinguish POAG from secondary disease and choose treatment for the individual risk.

Working copy published: 2026-11-06T03:47:16+01:00. Source, translation and medical checks remain open. Limitations are stated in the text and references. Editorial text version: 2026-11-04 06:13 CET.

Early recognition and sustained treatment reduce the risk of further irreversible loss. Pressure lowering remains the established disease-directed strategy; normal pressure does not exclude glaucoma and successful treatment does not guarantee lifelong stability.

Terminology and draft status

Selected WHO UMD terminology access is carried forward from review010 and documented in the terminology ledger. Compound terms and full Arabic clinical translation remain working copies requiring further review. Source limits remain explicit.

01Recognise glaucoma beyond the pressure reading

Primary open-angle glaucoma (POAG) is a chronic progressive optic neuropathy with characteristic loss of retinal ganglion cells and their axons. Raised intraocular pressure (IOP) is an important modifiable risk factor, but neither a high reading nor a normal reading establishes or excludes glaucoma. 1

Mechanical stress at the lamina cribrosa, disturbed axonal transport, vascular dysregulation and oxidative injury are complementary proposed mechanisms. Reactive oxygen species are not simply unbound oxygen atoms. These hypotheses do not establish a proven vascular or antioxidant treatment for preserving vision. 1

Aqueous humour leaves mainly through the trabecular meshwork and Schlemm canal, with an additional uveoscleral route. Understanding outflow helps explain pressure-lowering treatments; distinguishing primary disease from a secondary open-angle mechanism remains essential. 1

A 2014 systematic review estimated glaucoma prevalence at 3.54% (95% credible interval 2.09–5.82) in people aged 40–80 years. This historical, age-defined estimate is not a current rate for the entire population; case definitions, sampling and geographical coverage limit comparisons. 5

02Use risk factors in their proper population

Older age, family history, myopia and population background help identify people needing careful assessment. African ancestry and some studied Latino populations have higher disease burdens, but group labels do not replace individual findings or account for access to care and other confounding. 1

The Baltimore Eye Survey found an age-adjusted odds ratio of 3.69 for a reported affected sibling, compared with 2.17 for a parent and 1.12 for a child. This cross-sectional, interview-based association is not one universal risk multiplier for all first-degree relatives. Early-onset familial disease can involve MYOC; testing requires an appropriate clinical context. 6 1

Central corneal thickness (CCT) influences applanation readings and predicts conversion in ocular-hypertension cohorts. OHTS found an adjusted hazard ratio of 3.4 (95% CI 2.1–5.6) for CCT ≤555 µm versus >588 µm, without an apparent threshold effect. This does not mean that thinning an individual cornea causes a fixed increase in glaucoma risk. 1 2

Corneal hysteresis (CH) describes a biomechanical damping response. A prospective glaucoma cohort associated lower CH with faster visual-field loss, but this is prognostic association rather than evidence that measuring or altering CH improves vision. CCT and CH answer different questions; neither replaces the optic nerve and field assessment. 1 4

03Measure pressure and interpret corneal effects

Goldmann applanation tonometry (GAT) remains the reference method in EGS6. Check calibration, technique, tear film, lid pressure and corneal history. Confirm unexpected or borderline readings and consider timing; urgent dangerous pressure or other acute findings should not be left untreated merely to obtain a routine diurnal profile. 1

The Ocular Response Analyzer (ORA) records inward and outward air-puff applanation pressures P1 and P2. Their difference contributes to CH and their average to Goldmann-correlated pressure. Corneal-compensated pressure (IOPcc) is less affected by some corneal properties, not independent of all corneal effects or universally more accurate in every eye. 1 9

The manufacturer’s derivation uses IOPcc = m1 × (P2 + k × P1) + b1, with calibration slope and offset; k was approximately −0.43 in the reported LASIK data. Thus P2 − 0.43 × P1 is a simplified component, not the complete calibrated pressure formula. The original conference attribution and timing claim are not proof of a new reference standard. 9

After corneal refractive surgery, applanation can underestimate pressure. Interpret CCT with the reading and clinical context; do not apply a universal numerical correction. Repeated good-quality measurements and longitudinal consistency matter more than choosing a device from an isolated lecture claim. 1

04Connect disc, OCT and visual field

Examine the neuroretinal rim and RNFL with photographs for comparison. The inferior–superior–nasal–temporal (ISNT) pattern is a useful clue, not a diagnostic rule that all healthy discs obey. Disc size, tilt and high myopia can substantially change the appearance. 1

Disc haemorrhages (Drance or splinter haemorrhages) are associated with a greater risk of progression. Document the finding, reassess pressure, adherence, structure and fields, and review the target and follow-up plan. A haemorrhage is neither the only sign of progression nor proof that immediate escalation is always required. 1

OCT assesses the optic nerve head, peripapillary RNFL and macular ganglion-cell measures such as GCC, GC-IPL and GCL. They are complementary, device-dependent measurements. Inspect segmentation, image quality, myopia and the floor effect; a nominal axial resolution does not prove universal superiority of macular imaging. 1

Reliable standard automated perimetry, for example 24-2 or 30-2 strategies, assesses function and change over time. Add denser central testing when the pattern warrants it. Structural and functional abnormalities can appear at different times; apparent normality of one does not justify omitting the other. 1

05Separate OHT, NTG and secondary mechanisms

Gonioscopy is needed to establish an open angle and detect pigmentation, pseudoexfoliation, synechiae or another secondary mechanism. A deep-looking anterior chamber or an imaging estimate does not replace direct angle assessment. Primary and secondary open-angle disease can require different treatment and monitoring. 1

Ocular hypertension (OHT) describes untreated IOP >21 mmHg without glaucomatous disc/RNFL or field damage, with an open angle and no secondary cause. Treatment depends on repeated pressure, conversion risk, life expectancy and preferences. EGS6 generally offers treatment for repeated pressures in the high twenties; there is no universal wait-until-32 rule. 1 2 3

OHTS randomised 1636 people with ocular hypertension to drops or observation. Its reported 60-month POAG frequency was 4.4% versus 9.5%; the trial’s pressure ceiling was an eligibility criterion, not a treatment threshold. Conversion to an early disc/field endpoint is not the same outcome as blindness, and absolute benefit depends on baseline risk. 2 3

NTG belongs to the POAG spectrum when characteristic damage occurs despite untreated readings within the statistical normal range. Review prior pressures, cornea and structure–function agreement. Disproportionate pallor, unexplained acuity/colour loss, rapid atypical change or neurological symptoms warrant targeted differential work-up for compression, inflammation or another neuropathy; routine MRI is not mandatory for every case. 1 14

06Set a target and coordinate treatment

Set a target for each eye from untreated pressure, damage, measured progression, life expectancy, fellow-eye status and treatment burden. An initial 20–30% reduction may be a useful stage-dependent reference, not a universal minimum or a guarantee of stability. Revise the absolute and relative target when the clinical course changes. 1

Prostaglandin analogues such as latanoprost are usual first-choice medication because of effective pressure lowering and convenient dosing. Select treatment for the patient’s eye, comorbidities, contraindications and preferences. Preservative-free formulations can help ocular-surface tolerance; they do not automatically lower pressure better or guarantee later surgical success. 1

Diastolic ocular perfusion pressure (DOPP) is commonly approximated as DOPP = DBP − IOP, where DBP is diastolic blood pressure. It is a derived proxy, not a direct measure of optic-nerve blood flow. Observational low-pressure associations do not establish one universal treatment threshold or prove that changing systemic medication prevents progression. 1 7 8

Ask about hypotensive symptoms, cardiovascular treatment and suspected sleep apnoea. Coordinate indicated ambulatory blood-pressure assessment and general medical care. Do not tell every NTG patient to avoid evening antihypertensives or independently change a cardiovascular regimen; proven systemic benefits and individual risks must be considered together. 1 8

07Choose SLT for the mechanism and indication

LiGHT supports selective laser trabeculoplasty (SLT) as an initial option for suitable OHT or open-angle glaucoma. It can reduce dependence on daily drops, but attendance and monitoring remain necessary. Response and retreatment vary; neither a fixed duration nor freedom from all future medication or surgery is guaranteed. 1 10 11 12

Angle visibility, pigmentation, baseline pressure, prior response and the device protocol guide treatment. A trial’s treatment extent or spot count is not a universal prescription. Titrate energy to the clinical/device context and plan pressure-spike prophylaxis and review rather than transferring an unverified fixed range to every eye. 1 10

In pigment dispersion, posterior iris bowing and reverse pupillary block can contribute to pigment release and trabecular dysfunction. YAG peripheral iridotomy may alter iris configuration, but this anatomical change does not establish prevention of glaucoma or visual-field loss. Evidence for routine iridotomy is uncertain; consider selected indications rather than a blanket rule. 1 13

Dense trabecular pigment increases concern for pressure spikes after laser trabeculoplasty. Use particular caution with energy, prophylaxis and early pressure assessment. Pigmentary glaucoma evidence and risks cannot be assumed identical to the mild/moderate POAG populations supporting routine first-line SLT. 1

08Confirm progression and plan lifelong care

Before judging treatment insufficient, check actual use, drop technique, tolerability, pressure timing and repeatable structural or functional change. If the target is unmet or progression threatens useful vision, consider additional medication, suitable laser or surgery matched to the required reduction and the eye’s mechanism. 1

Follow-up frequency depends on severity, progression, treatment changes and ability to return. Stable disease does not mean that every visit needs every test, or that one fixed interval is safe for all. Explain lifelong surveillance and agree a practical plan for the patient’s priorities and access to care. 1

Sudden visual loss, severe eye pain, haloes with nausea/vomiting or concerning neurological symptoms require urgent assessment. These features should not be attributed to ordinary chronic POAG without examination. Acute angle closure and other emergencies remain possible even in someone previously labelled an open-angle patient. 1

Confirm progression and plan lifelong care
ParameterFinding and contextClinical implication
IOP/OHTRepeated pressure with normal disc/fieldOHTS eligibility ceiling is not an absolute treatment threshold; assess conversion risk
CCTInterpret with tonometry and the OHT risk modelNo universal thin-cornea cutoff or fixed pressure correction
CHBiomechanical and prognostic informationAssociation does not prove clinical benefit or replace standard testing
Diastolic OPPDOPP = DBP − IOPDerived proxy; no automatic systemic-drug change or universal treatment threshold
SLTSuitable OHT/open-angle indication and angle anatomyVariable response/duration; pigmentation, prophylaxis and monitoring matter
Disc haemorrhageDocumented Drance/splinter haemorrhageReassess risk, tests, target and follow-up; escalation is individual
IOPccCalibrated ORA-derived pressureSimplified P1/P2 expressions omit calibration; not a universal new reference standard
NTG progresses despite IOP of 12 mmHg: what next?

Confirm repeatable progression, pressure history and treatment use; reconsider the target and atypical findings. Assess systemic hypotension or sleep apnoea when indicated with the appropriate team; ambulatory BP testing is not a substitute for eye assessment.

Why assess trabecular pigmentation before SLT?

It affects energy selection and pressure-spike risk. Titrate using clinical findings and the device protocol, with suitable prophylaxis and review; the original fixed energy range is not a universal instruction.

What does IOPcc add to GAT?

A biomechanically informed estimate less affected by some corneal properties. It remains method-dependent; calibrated output, quality and context matter, and universal superiority is not established.

What pressure target should POAG treatment aim for?

Set an absolute and relative target for each eye from baseline pressure, damage, progression and lifetime visual risk; reassess benefit, tolerance and burden. A percentage alone is insufficient.

How often should stable glaucoma be reviewed?

Choose intervals and tests for severity, demonstrated progression, treatment changes and reliability. The original 3–6-month schedule is a teaching reference, not a universal rule that every stable visit requires every test.

References and access status

  1. 1
    EGS Terminology and Guidelines for Glaucoma,6th edition (2025)

    Supplied local PDF: selected tonometry/CCT pp75–80, disc/OCT pp93–102, OHT/PG pp127–131, POAG/juvenile pp124–126 and treatment pp160–164; relevant text only. Additional appraisal carried forward from reviews008–010. No complete-book/figure reading claimed.

  2. 2
    Gordon et al. OHTS baseline risk factors (2002),DOI10.1001/archopht.120.6.714

    Complete primary abstract, methods, selected results/table3 and extracted figure captions read from the trial-hosted PDF. Figure pixels and complete narrative not newly read. CCT measured after randomisation; prediction is not causation.

  3. 3
    Kass et al. OHTS randomised trial (2002),DOI10.1001/archopht.120.6.701

    Trial identity verified; results/design accessed through the primary companion risk-factor report and supplied EGS passages. Complete main trial report not newly read here. Eligibility is not a treatment recommendation.

  4. 4
    Medeiros et al. Corneal hysteresis and progression (2013),DOI10.1016/j.ophtha.2013.01.032

    Indexed primary abstract/result and selected primary methods passages inspected; direct PubMed incomplete and PMC challenge. Full report not read. Prospective observational association, not a test-guided intervention trial.

  5. 5
    Tham et al. Global glaucoma prevalence (2014),DOI10.1016/j.ophtha.2014.05.013

    Complete indexed primary abstract read; main report/supplements not read. Historical age-defined meta-analysis; uncertainty interval is credible, not a confidence interval.

  6. 6
    Tielsch et al. Family history,Baltimore Eye Survey (1994),DOI10.1001/archopht.1994.01090130079022

    Complete primary abstract directly read; full report unread. Interview-based cross-sectional odds,relationship-specific and susceptible to awareness/selection bias.

  7. 7
    Tielsch et al. Hypertension/perfusion pressure,Baltimore (1995),DOI10.1001/archopht.1995.01100020100038

    Primary identity/design located; full abstract/report not successfully retrieved. Original exact threshold is not verified. Vascular clinical interpretation is supported by EGS and Charlson,not an unseen table here.

  8. 8
    Charlson et al. Nocturnal hypotension/progression (2014)

    Primary abstract appraisal carried forward from reviews009/010; full report not newly read. Observational NTG association,not proof of benefit from changing antihypertensives.

  9. 9
    Luce/Reichert. Methodology for corneal-compensated IOP and CRF

    Manufacturer-hosted original technical poster text and extracted formula read. Figure pixels not inspected; not a current IFU or an independent clinical-outcome trial. Calibration and manufacturer employment/proprietary interests matter.

  10. 10
    Gazzard et al. LiGHT primary trial (2019),DOI10.1016/S0140-6736(18)32213-X

    Source appraisal carried forward from review008 and supplied EGS; complete protocol/supplements not newly read. Selected OHT/OAG population and UK setting limit transfer to every secondary glaucoma or laser protocol.

  11. 11
    LiGHT six-year results (2023)

    Abstract appraisal carried forward from review008; full report not newly read. Read with the2025 correction; superseded surgical counts are not repeated.

  12. 12
    LiGHT corrigendum (2025),DOI10.1016/j.ophtha.2025.07.029

    Indexed correction access carried forward from008/010; full corrected tables remain unread after403. No full-correction verification claimed.

  13. 13
    Cochrane. Peripheral iridotomy for pigmentary glaucoma (2016),PMID26871761

    Indexed review abstract/selected results and trial-characteristics passages read; complete review/primary trials not read. Very-low-certainty evidence and differing populations/outcomes; iris anatomy is not visual-field benefit.

  14. 14
    Kosior-Jarecka et al. Atypical NTG neuroimaging (2020),DOI10.1155/2020/9093206

    Complete primary abstract access carried forward from review010; full report unread. Selected atypical NTG cohort cannot establish routine MRI for all NTG.

  15. 15
    Original derivative lecture and three video links

    Complete existing page and companion topic read; snapshot preserved. Video content,spoken transcript and slides not inspected. Conference year,original exact quantitative/device parameters and spoken terminology remain unresolved.

Original lecture links